With the addition of a small plaque, Graeme Mitcheson’s beautiful sculptures could memorialise the countless animals who were ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

An Ohio woman bought a painting for $2.99 at a thrift store and it ended up being auctioned for $2,875 when it was found to ...

A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque ...

Newsweek spoke to a personal fashion stylist who revealed key ways to spot a real designer bag from a fake one and other ...

Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

Arcutis Biotherapeutics, Inc.’s ARQT share price has surged by 12.31%, which has investors questioning if this is right time to sell.

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

Zurcher Kantonalbank Zurich Cantonalbank decreased its position in shares of Option Care Health, Inc. (NASDAQ:OPCH – Free Report) by 31.0% during the fourth quarter, HoldingsChannel reports. The ...

US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...